Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Doxorubicin pathways: pharmacodynamics and adverse effects.

Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, Altman RB.

Pharmacogenet Genomics. 2011 Jul;21(7):440-6. doi: 10.1097/FPC.0b013e32833ffb56. No abstract available.

2.

Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl).

Working PK, Dayan AD.

Hum Exp Toxicol. 1996 Sep;15(9):751-85. Review. No abstract available.

PMID:
8880211
3.

[Inhibition of hydrogen peroxide, oxygen and semiquinone radicals in the development of drug resistance to doxorubicin in human erythroleukemia K562-cells].

Kalishina EV, Saprin AN, Solomka VS, Shchebrak NP, Piruzian LA.

Vopr Onkol. 2003;49(3):294-8. Review. Russian. No abstract available.

PMID:
12926210
4.

Pharmacogenetics of target genes across doxorubicin disposition pathway: a review.

Lal S, Mahajan A, Chen WN, Chowbay B.

Curr Drug Metab. 2010 Jan;11(1):115-28. Review.

PMID:
20302569
5.

Development and activities of the BR96-doxorubicin immunoconjugate.

Hellström I, Hellström KE, Senter PD.

Methods Mol Biol. 2001;166:3-16. Review. No abstract available.

PMID:
11217374
6.

Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes.

Tahover E, Patil YP, Gabizon AA.

Anticancer Drugs. 2015 Mar;26(3):241-58. doi: 10.1097/CAD.0000000000000182. Review.

PMID:
25415656
7.

A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity.

Ludke AR, Al-Shudiefat AA, Dhingra S, Jassal DS, Singal PK.

Can J Physiol Pharmacol. 2009 Oct;87(10):756-63. doi: 10.1139/Y09-059. Review.

PMID:
19898559
8.

Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol.

Pereira GC, Silva AM, Diogo CV, Carvalho FS, Monteiro P, Oliveira PJ.

Curr Pharm Des. 2011;17(20):2113-29. Review.

PMID:
21718248
9.

Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?

Kaklamani VG, Gradishar WJ.

Clin Breast Cancer. 2003 Apr;4 Suppl 1:S26-33. Review.

PMID:
12756076
10.

Cardiotoxicity of doxorubicin and other anthracycline derivatives.

Jain D.

J Nucl Cardiol. 2000 Jan-Feb;7(1):53-62. Review. No abstract available.

PMID:
10698235
11.

[Anthracycline drugs].

Matusewicz W, Robak T.

Pol Arch Med Wewn. 1985 Apr;73(4):242-9. Review. Polish. No abstract available.

PMID:
3916893

Supplemental Content

Support Center